OBJECTIVE: Familial Mediterranean fever (FMF) is thought to be a rare disorder in Japan, and the clinical features of Japanese patients with FMF remain unclear. Our aim was to elucidate the clinical characteristics of FMF in Japanese patients. METHODS: We analyzed clinical and genetic data of 80 patients based on the results of a nationwide questionnaire survey and review of the literature. RESULTS: From clinical findings of 80 Japanese patients, high-grade fever was observed in 98.8%, chest attacks (pleuritis symptoms) in 61.2%, abdominal attacks (peritonitis symptoms) in 55.0%, and arthritis in 27.5%. Twenty-four percent of patients experienced their first attacks before 10 years of age, 40% in their teens, and 36% after age 20 years. Colchicine was effective in many patients at a relatively low dose (< 1.0 mg/day). AA amyloidosis was seen in only 1 patient. Common MEFV mutation patterns were E148Q/M694I (25.0%), M694I alone (17.5%), and L110P/E148Q/M694I (17.5%), and no patient carried the M694V mutation, the most common mutation in Mediterranean patients with FMF. CONCLUSION: A larger than expected number of patients with FMF exist in Japan, and the clinical presentation of Japanese FMF patients seems to be relatively milder than those of Mediterranean FMF patients. AA amyloidosis rarely occurs in Japanese patients, probably due to difference in patterns of the MEFV genotype between Japanese and Mediterranean patients.
OBJECTIVE:Familial Mediterranean fever (FMF) is thought to be a rare disorder in Japan, and the clinical features of Japanese patients with FMF remain unclear. Our aim was to elucidate the clinical characteristics of FMF in Japanese patients. METHODS: We analyzed clinical and genetic data of 80 patients based on the results of a nationwide questionnaire survey and review of the literature. RESULTS: From clinical findings of 80 Japanese patients, high-grade fever was observed in 98.8%, chest attacks (pleuritis symptoms) in 61.2%, abdominal attacks (peritonitis symptoms) in 55.0%, and arthritis in 27.5%. Twenty-four percent of patients experienced their first attacks before 10 years of age, 40% in their teens, and 36% after age 20 years. Colchicine was effective in many patients at a relatively low dose (< 1.0 mg/day). AA amyloidosis was seen in only 1 patient. Common MEFV mutation patterns were E148Q/M694I (25.0%), M694I alone (17.5%), and L110P/E148Q/M694I (17.5%), and no patient carried the M694V mutation, the most common mutation in Mediterranean patients with FMF. CONCLUSION: A larger than expected number of patients with FMF exist in Japan, and the clinical presentation of Japanese FMFpatients seems to be relatively milder than those of Mediterranean FMFpatients. AA amyloidosis rarely occurs in Japanese patients, probably due to difference in patterns of the MEFV genotype between Japanese and Mediterranean patients.
Authors: K Migita; K Agematsu; K Yamazaki; A Suzuki; M Yazaki; Y Jiuchi; T Miyashita; Y Izumi; T Koga; A Kawakami; K Eguchi Journal: Clin Exp Immunol Date: 2011-03-25 Impact factor: 4.330
Authors: E Lainka; M Bielak; P Lohse; C Timmann; S Stojanov; R von Kries; T Niehues; U Neudorf Journal: Eur J Pediatr Date: 2012-08-19 Impact factor: 3.183
Authors: Ah Leum Lim; Hyun Joo Jang; Jung Wan Han; Yong Keun Song; Won Jun Song; Heung Jung Woo; Young Ok Jung; Sea Hyub Kae; Jin Lee Journal: J Korean Med Sci Date: 2012-10-30 Impact factor: 2.153